ClinicalTrials.gg
CompletedNCT03542877Updated Jul 15, 2022Results posted

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

A Phase 2 interventional study of Oral Tablet: Cabozantinib in Colorectal Cancer, sponsored by Academic Thoracic Oncology Medical Investigators Consortium. Completed at 10 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by Academic Thoracic Oncology Medical Investigators Consortium · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,341 studies in Colorectal Neoplasms with a site in United States — 417 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,173rd of 1,933
44 · median 64
Started
2018
with 95 others
Phase 2
511 of 2,341
66 open now
Registered
1,253rd of 2,341
by date

Among the 2,341 studies in Colorectal Neoplasms with a site in United States, this one is the 1,173rd largest by enrollment of the 1,933 interventional ones that give a count, is one of 96 that started in 2018, is one of 511 in phase 2, and was the 1,253rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

417 of the 2,341 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 417 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,341 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.

Read the detailed description

This is a phase II clinical trial that seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment. This study is a two stage study that will first measure (up to) 16 patients' progression free survival (PFS). Stage two will, again, measure PFS, but in a population (up to) 28 patients.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Cabozantinib
  • Progression Free Survival
  • Metastatic Colorectal Cancer
  • Tumor
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has a histologic or cytologic diagnosis of colorectal adenocarcinoma that is or unresectable and is to or progressed (or relapsed) following a fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab; prior epidermal growth factor inhibitor therapy is required for patients with left-sided, RAS wild-type tumors; prior FDA-approved inhibitor therapy is required for patients with MSI-H colorectal cancer. Prior regorafenib or TAS-102 treatment is not required.
  2. per 1.1 as determined by the investigator.
  3. The subject has had an assessment of all known disease sites e.g., by computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within 28 days before the first dose of cabozantinib.
  4. The subject is ≥ 18 years old on the day of consent.
  5. The subject has an (ECOG) performance status of 0 or 1.
  6. Recovery to baseline or ≤ Grade 1 v.4.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  7. Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and/or tumor block).
  8. The subject has organ and marrow function and laboratory values as follows within 7 days before the first dose of cabozantinib:

    1. ≥ 1500/mm3 without colony stimulating factor support;
    2. ≥ 100,000/mm3;
    3. ≥ 9 g/dL;
    4. ≤ 1.5 x . For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg/dL;
    5. Serum albumin ≥ 2.8 g/dl;
    6. Serum creatinine ≤ 1.5 x ULN or (CrCl) ≥ 40 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:

      • Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72);
      • Female: Multiply above result by 0.85;
    7. and AST ≤ 3.0 x ULN;
    8. Lipase \< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis;
    9. UPCR ≤ 1;
    10. Serum phosphorus, calcium, magnesium and potassium ≥ LLN.
  9. The subject is capable of understanding and complying with the protocol requirements and has signed the document.
  10. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s).

Exclusion criteria

Exclusion Criteria:

  1. The subject has received cytotoxic chemotherapy (including cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment;
  2. Prior treatment with cabozantinib;
  3. Radiation therapy for bone within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with ongoing complications from prior radiation therapy are not eligible;
  4. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 14 days before the first dose of study treatment. Note: Subjects with prostate cancer currently receiving LHRH or GnRH agonists may be maintained on these agents;
  5. The subject has received any other type of investigational agent within 28 days before the first dose of study treatment;
  6. Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without treatment at the time of the start of study treatment;
  7. The subject has (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory within 7 days before the first dose of study treatment;
  8. Concomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or inhibitors (eg, clopidogrel); Note: Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (\< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 12 weeks before randomization, and who have had no complications from a thromboembolic event or the anticoagulation regimen. ;
  9. The subject has experienced any of the following:

    1. clinically-significant GI bleeding within 6 months before the first dose of study treatment;
    2. hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment;
    3. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment.
  10. The subject has radiographic evidence of cavitating pulmonary lesion(s);
  11. The subject has tumor invading or encasing any major blood vessels;
  12. The subject has evidence of clinically significant bleeding from tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib;
  13. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    a. Cardiovascular disorders including: i. Congestive heart failure (CHF): (NYHA) Class III (moderate) or Class IV (severe) at the time of screening; ii. Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment; iii. Any history of congenital long syndrome; iv. Any of the following within 6 months before the first dose of study treatment:

    • unstable angina pectoris;
    • clinically-significant cardiac arrhythmias;
    • stroke (including (TIA), or other ischemic event);
    • myocardial infarction;
    • thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena cava filter) are not eligible for this study).

      b. GI disorders particularly those associated with a high risk of perforation or fistula formation including: i. Active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction ii. Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months before randomization, Note: Complete healing of an intra-abdominal abscess must be confirmed prior to randomization c. Other clinically significant disorders that would preclude safe study participation;

  14. Major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible;
  15. QTcF > 500 msec within 1 month before the first dose of study treatment:

    a. Three ECGs must be performed for eligibility determination. If the average of these three consecutive results for QTcF is ≤ 500 msec, the subject meets eligibility in this regard.

  16. Pregnant or lactating females;
  17. Inability to swallow intact tablets;
  18. Previously identified allergy or to components of the study treatment formulations;
  19. Diagnosis of another within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy;
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Oral Cabozantinib

    Patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.

    Drug: Oral Tablet: Cabozantinib

Interventions

  • Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.

    Also known as: Cometriq, Cabometyx

06

What researchers measure

Primary outcomes

  1. 12-Week Progression Free Survival

    A patient is classified as progression-free if s/he is assessed as not having progressive disease (PD) as defined per RECIST 1.1 criteria at either the 12-week assessment or after having at least 11 weeks of treatment for subjects without the 12-week assessment. Censored patients (i.e. those who have not progressed but who are missing a 12-week assessment) are not included in the analysis. Subjects who didn't have the 12-week assessment but who had clinical progression were included and considered to have progressed. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.

Secondary outcomes

  1. 12-Week Progression-Free Survival by RAS Mutation Status

    This has the same outcome measure description as the primary analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.

  2. 12-Week Progression-Free Survival by PIK3CA Mutation Status

    This has the same outcome measure description as the primary analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.

  3. Progression-Free Survival (PFS)

    Progression-free survival will be defined as the time from administration of the initial dose of cabozantinib to evidence of radiographic progression as defined by RECIST criteria or death from any cause without evidence of disease progression, whichever occurs first. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

  4. Progression-Free Survival (PFS) by RAS Mutation Status

    This has the same outcome measure description as the PFS analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

  5. Progression-Free Survival (PFS) by PIK3CA Mutation Status

    This has the same outcome measure description as the PFS analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

  6. Response Rate in Patients With CRC Treated With Cabozantinib

    \*A patient is classified as a responder if s/he is assessed as having complete response or partial response (CR or PR) at the time of any assessment, where CR and PR are defined per RECIST 1.1 criteria.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

  7. Overall Survival (OS) in Patients With CRC Treated With Cabozantinib

    Overall Survival will be defined as the time from administration of the initial dose of cabozantinib until death from any cause.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

  8. Overall Survival (OS) by RAS Mutation Status

    This has the same outcome measure description as the OS analysis.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

  9. Overall Survival (OS) by PIK3CA Mutation Status

    This has the same outcome measure description as the OS analysis.

    Time frame: Study start date to study end date, or death, whichever comes first, up to 24 months

07

Results

Posted Jun 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneOral Cabozantinib
Started44
Completed23
Not completed21

Outcome measures

Primary12-Week Progression Free Survival

A patient is classified as progression-free if s/he is assessed as not having progressive disease (PD) as defined per RECIST 1.1 criteria at either the 12-week assessment or after having at least 11 weeks of treatment for subjects without the 12-week assessment. Censored patients (i.e. those who have not progressed but who are missing a 12-week assessment) are not included in the analysis. Subjects who didn't have the 12-week assessment but who had clinical progression were included and considered to have progressed. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
Reported as:
Count of participants · Participants
12-Week Progression Free Survival
ParticipantsOral Cabozantinib
12-Week Progression Free Survival18
Secondary12-Week Progression-Free Survival by RAS Mutation Status

This has the same outcome measure description as the primary analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
Reported as:
Count of participants · Participants
12-Week Progression-Free Survival by RAS Mutation Status
ParticipantsRAS MutantRAS Wild Type
12-Week Progression-Free Survival by RAS Mutation Status711
Secondary12-Week Progression-Free Survival by PIK3CA Mutation Status

This has the same outcome measure description as the primary analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
Reported as:
Count of participants · Participants
12-Week Progression-Free Survival by PIK3CA Mutation Status
ParticipantsPIK3CA MutantPIK3CA Wild Type
12-Week Progression-Free Survival by PIK3CA Mutation Status311
SecondaryProgression-Free Survival (PFS)

Progression-free survival will be defined as the time from administration of the initial dose of cabozantinib to evidence of radiographic progression as defined by RECIST criteria or death from any cause without evidence of disease progression, whichever occurs first. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Median · Weeks
Progression-Free Survival (PFS)
WeeksOral Cabozantinib
Progression-Free Survival (PFS)13 (9 to 21)
SecondaryProgression-Free Survival (PFS) by RAS Mutation Status

This has the same outcome measure description as the PFS analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Median · Weeks
Progression-Free Survival (PFS) by RAS Mutation Status
WeeksRAS MutantRAS Wild Type
Progression-Free Survival (PFS) by RAS Mutation Status12 (6 to 14)21 (9 to 48)
SecondaryProgression-Free Survival (PFS) by PIK3CA Mutation Status

This has the same outcome measure description as the PFS analysis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Median · Weeks
Progression-Free Survival (PFS) by PIK3CA Mutation Status
WeeksPIK3CA MutantPIK3CA Wild Type
Progression-Free Survival (PFS) by PIK3CA Mutation Status26 (5 to NA)20 (6 to 29)
SecondaryResponse Rate in Patients With CRC Treated With Cabozantinib

\*A patient is classified as a responder if s/he is assessed as having complete response or partial response (CR or PR) at the time of any assessment, where CR and PR are defined per RECIST 1.1 criteria.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Count of participants · Participants
Response Rate in Patients With CRC Treated With Cabozantinib
ParticipantsOral Cabozantinib
Response Rate in Patients With CRC Treated With Cabozantinib1
SecondaryOverall Survival (OS) in Patients With CRC Treated With Cabozantinib

Overall Survival will be defined as the time from administration of the initial dose of cabozantinib until death from any cause.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Median · Weeks
Overall Survival (OS) in Patients With CRC Treated With Cabozantinib
WeeksOral Cabozantinib
Overall Survival (OS) in Patients With CRC Treated With Cabozantinib36 (24 to 50)
SecondaryOverall Survival (OS) by RAS Mutation Status

This has the same outcome measure description as the OS analysis.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Median · Weeks
Overall Survival (OS) by RAS Mutation Status
WeeksRAS MutantRAS Wild Type
Overall Survival (OS) by RAS Mutation Status30 (18 to 46)45 (20 to NA)
SecondaryOverall Survival (OS) by PIK3CA Mutation Status

This has the same outcome measure description as the OS analysis.

Time frame:
Study start date to study end date, or death, whichever comes first, up to 24 months
Reported as:
Median · Weeks
Overall Survival (OS) by PIK3CA Mutation Status
WeeksPIK3CA MutantPIK3CA Wild Type
Overall Survival (OS) by PIK3CA Mutation Status92 (9 to NA)36 (20 to 85)

Adverse events

Collected over 45 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Cabozantinib5/44 (11.4%)20/44 (45.5%)43/44 (97.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventOral Cabozantinib
Pleural EffusionRespiratory, thoracic and mediastinal disorders3/44
Disease ProgressionGeneral disorders2/44
dyspneaRespiratory, thoracic and mediastinal disorders2/44
GI bleedGastrointestinal disorders2/44
Lung infectionRespiratory, thoracic and mediastinal disorders2/44
Cavitating Pulmonary NodulesRespiratory, thoracic and mediastinal disorders1/44
Abdominal PainGastrointestinal disorders1/44
Acute Cerebrovascular AccidentGeneral disorders1/44
Acute PancreatitisGastrointestinal disorders1/44
Acute Renal FailureRenal and urinary disorders1/44
Most frequent other events
Showing 10 of 124
Most frequent other events
EventOral Cabozantinib
FatigueGeneral disorders28/44
DiarrheaGastrointestinal disorders23/44
NauseaGeneral disorders17/44
PainGeneral disorders17/44
Abdominal PainGastrointestinal disorders16/44
AnorexiaGeneral disorders16/44
HypertensionBlood and lymphatic system disorders15/44
ConstipationGastrointestinal disorders14/44
palmar-plantar erythrodysesthesiaSkin and subcutaneous tissue disorders14/44
Weight lossMetabolism and nutrition disorders14/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oral Cabozantinib
<=18 years0
Between 18 and 65 years33
>=65 years11
Age, Continuous
Age, Continuous(years)Oral Cabozantinib
Mean54 ± 23
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Oral Cabozantinib
Female13
Male30
Unknown1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Cabozantinib
Hispanic or Latino6
Not Hispanic or Latino37
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Cabozantinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White38
More than one race0
Unknown or Not Reported5
Region of Enrollment
Region of Enrollment(participants)Oral Cabozantinib
United States44
08

Study locations

10 sites
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Kenneth Norris Jr. Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Universtiy of Colorado Denver
    Aurora, Colorado 80045, United States
  • Lone Tree Health Center
    Lone Tree, Colorado 80124, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Jefferson Abington Hospital
    Abington, Pennsylvania 19001, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Oct 2020, 28 months.

Results were first posted in Jun 2022, 1 year 7 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 28 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2018
First posted
May 31, 2018
StartActual
Jun 1, 2018
Primary completionActual
Oct 19, 2020
CompletionActual
Mar 7, 2022
Results first posted
Jun 2, 2022
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03542877
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Responsible party
Sponsor
First posted
May 31, 2018
Start date
Jun 1, 2018
Primary completion
Oct 19, 2020
Completion
Mar 7, 2022
Results posted
Jun 2, 2022
Last update
Jul 15, 2022

Study contacts

Wells Messersmith, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion